Dataset Information

Resection of urachal anomalies in dogs with recurrent lower urinary tract disease.

ABSTRACT:

Objective

To determine whether surgical removal of urachal anomalies improves the outcomes of dogs with recurrent lower urinary tract disease (LUTD) and bacterial urinary tract infection (BUTI).

Study design

Retrospective study.

Animals

Thirty-three dogs with urachal anomalies and recurrent LUTD or BUTI.

Methods

Medical records of dogs with LUTD or BUTI and a diagnosis of urachal anomaly treated by partial cystectomy were reviewed. A minimum follow-up of 9?months was required for inclusion.

Results

Median age at onset of clinical signs was 12?months (range, 1?month to 10?years). Urachal anomalies were detected with histopathology in 20 of 28 (71%) dogs. At a median follow-up of 22?months (range, 9-114), 21 of 28 (64%) dogs were free of signs of LUTD. Nine (27%) dogs exhibited reduced signs of LUTD; in three (9%) dogs, no clinical improvement was observed. Among the 25 dogs with confirmed preoperative BUTI, 22 clinically improved with surgery.

Conclusion

Partial cystectomy reduced the long-term severity of clinical signs and risk of recurrence of LUTD or BUTI in dogs with confirmed or suspected urachal anomalies.

Clinical significance

Partial cystectomy should be considered as an adjunct to the treatment of LUTD and BUTI in dogs.

SUBMITTER: Visser J

PROVIDER: S-EPMC6973151 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Resection of urachal anomalies in dogs with recurrent lower urinary tract disease.

Visser Judith J Kummeling Anne A van Nugteren Marjon A MA Grinwis Guy C M GCM Brocks Bouvien A W BAW

Veterinary surgery : VS 20190814 1

<h4>Objective</h4>To determine whether surgical removal of urachal anomalies improves the outcomes of dogs with recurrent lower urinary tract disease (LUTD) and bacterial urinary tract infection (BUTI).<h4>Study design</h4>Retrospective study.<h4>Animals</h4>Thirty-three dogs with urachal anomalies and recurrent LUTD or BUTI.<h4>Methods</h4>Medical records of dogs with LUTD or BUTI and a diagnosis of urachal anomaly treated by partial cystectomy were reviewed. A minimum follow-up of 9 months was ...[more]

PMID: 31414491

Similar Datasets

Project description:The diseases of the lower urinary tract are traditionally divided into abnormalities of storage and abnormalities of emptying. The targets for therapy were the organs most responsible for influencing storage and emptying. Modern understanding places the symptomatic status of the patient as the overriding criterion for treatment. It also accommodates a broader understanding of multiple and overlapping systems. Symptoms of voiding dysfunction have been clearly shown to be associated with symptoms of other genitourinary disease, for example, erectile dysfunction (ED). Treatment of voiding dysfunction has also been shown to have effects (adverse or beneficial) in these other domains. Thus, the symptoms of lower urinary tract disease (LUTD) that have to be considered now as targets relevant to these therapies include ED, ejaculatory dysfunction, sexual desire, sexual pain disorders and female sexual dysfunction. The anatomic, neural and endocrine systems that support these symptomatic functions and dysfunctions span the range from the urogenital smooth muscle to the hypothalamus, the bladder sensory output to the micturition centre and growth factors to androgens. Potentially important targets also include vascular and spinal structures, sex hormones and nitric oxide as well as the obvious genes, enzymes and receptors. The epidemiological studies prove the convergence of LUTD when viewed through the lens of the current patient-related outcomes and problem constructs. This convergence serves as a clear guidance to include wide ranging outcome instruments in all future studies with compounds being investigated for the treatment of LUTD. Out of these will come evidence of expected and unexpected collateral effects. The convergence should open the possibility to a different business model for developing therapeutic concepts. The blockbuster drug for a monolithic indication may be supplemented by agents with single or multiple pathway activity with smaller parallel targets. Using an approach based on patient reported outcomes to therapeutic targets not only widens the range of conditions, but also the patient types who can be considered as having LUTD.

Dataset Information

Resection of urachal anomalies in dogs with recurrent lower urinary tract disease.

Objective

Study design

Animals

Methods

Results

Conclusion

Clinical significance

Publications

Resection of urachal anomalies in dogs with recurrent lower urinary tract disease.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure